Opnurasib (JDQ Jdq443 Clinical Trial Nct Kras G12c
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review In the beginning of January 2021, Novartis KRAS G12C inhibitor compound JDQ443 is undergoing a phase Ib/II clinical trial as a monotherapy and For example, you may enter the name of a drug or the NCT number Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation. Study Details | NCT04699188 | Study of JDQ443 in Patients With A summary of the published clinical trials of KRASG12C inhibitors in patients with NSCLC is presented in Table 1. Table 1. KRASG12C Inhibitors ...